Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Cash & Equivalents (2019 - 2025)

Korro Bio's Cash & Equivalents history spans 7 years, with the latest figure at $21.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 60.78% year-over-year to $21.8 million, compared with a TTM value of $21.8 million through Dec 2025, down 60.78%, and an annual FY2025 reading of $21.8 million, down 60.78% over the prior year.
  • Cash & Equivalents for Q4 2025 was $21.8 million at Korro Bio, down from $24.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $169.2 million in Q1 2021, with the low at $21.8 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $72.5 million, with a median of $52.7 million recorded in 2022.
  • Year-over-year, Cash & Equivalents plummeted 70.55% in 2022 and then skyrocketed 357.3% in 2023.
  • Tracing KRRO's Cash & Equivalents over 5 years: stood at $79.6 million in 2021, then tumbled by 54.38% to $36.3 million in 2022, then skyrocketed by 357.3% to $166.2 million in 2023, then tumbled by 66.51% to $55.6 million in 2024, then crashed by 60.78% to $21.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Cash & Equivalents are $21.8 million (Q4 2025), $24.2 million (Q3 2025), and $33.6 million (Q2 2025).